一分钟看懂
这是一项关于白血病的III 期研究，登记的药物或干预包括Sonrotoclax；Zanubrutinib；Acalabrutinib；Venetoclax，当前状态为招募中。登记地点显示中国北京、重庆、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sonrotoclax；Zanubrutinib；Acalabrutinib；Venetoclax · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking Union Medical College Hospital · 北京
- The First Affiliated Hospital of Chongqing Medical University · 重庆
- The First Affiliated Hospital of Fujian Medical University · 福州
- Zhujiang Hospital of Southern Medical University · 广州
- Sun Yat Sen University Cancer Center Huangpu Branch · 广州
- The First Affiliated Hospital of Guangxi Medical University · 南宁
- Guizhou Provincial Peoples Hospital · 贵阳
- Harbin Medical University Cancer Hospital · 哈尔滨
- Henan Cancer Hospital · 郑州
- The Second Xiangya Hospital of Central South University · 长沙
- Jiangsu Province Hospital · 南京
- Affiliated Hospital of Nantong University · 南通
- The Second Affiliated Hospital of Nanchang University · 南昌
- The Second Affiliated Hospital of Xian Jiaotong University · 西安
- Shandong Provincial Hospital · 济南
- Rui Jin Hospital Shanghai Jiao Tong University School of Medicine · 上海
- Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital · 成都
- Institute of Hematology and Hospital of Blood Disease · 天津
- First Affiliated Hospital of Kunming Medical University · 昆明
- The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan · 杭州
公开的入选条件
- * Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
- * Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- * Measurable disease by Computer Tomography/Magnetic Resonance Imaging
- * Adequate bone marrow and organ function
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07277231；登记信息更新于 2026-09-11。